\begin{center}
\begin{scriptsize}
\begin{longtable}
{l>{\raggedright\arraybackslash}p{2.5cm}>{\raggedright\arraybackslash}p{2cm}lp{2cm}lp{1.5cm}p{1.5cm}}
\caption{\textbf{Categorical associations: Significant results}. In many cases we tested a genotype against all other genotypes, shown using the symbol for set complement in the table ($\complement$). For biallelic genotypes, the variant of reference is shown and the genotype is symbolized as $1/1$ (homozygous), $1/\complement$, and $\complement/\complement$ --heterozygous for "other". MAPT: MAPT Interaction domain.  hdim: homodimerization. }
\label{tab:fet} \\
\hline
\multicolumn{1}{c}{\textbf{cohort}} & \multicolumn{1}{c}{\textbf{HPO}} & \multicolumn{1}{c}{\textbf{genotype (A)}} & \multicolumn{1}{c}{\textbf{Counts (A)}} & \multicolumn{1}{c}{\textbf{genotype (B)}} & \multicolumn{1}{c}{\textbf{Counts (B)}} & \multicolumn{1}{c}{\textbf{p-val}} & \multicolumn{1}{c}{\textbf{adj. p-val}}\\ \hline
\endfirsthead
\multicolumn{8}{c}%

{{\bfseries \tablename\ \thetable{} -- continued from previous page}} \\ 

\hline
\multicolumn{1}{c}{\textbf{cohort}} & \multicolumn{1}{c}{\textbf{HPO}} & \multicolumn{1}{c}{\textbf{genotype (A)}} & \multicolumn{1}{c}{\textbf{Counts (A)}} & \multicolumn{1}{c}{\textbf{genotype (B)}} & \multicolumn{1}{c}{\textbf{Counts (B)}} & \multicolumn{1}{c}{\textbf{p-val}} & \multicolumn{1}{c}{\textbf{adj. p-val}}\\ \hline
\endhead 
\hline \multicolumn{8}{|r|}{{Continued on next page}} \\ \hline 

\endfoot 
\hline \hline 
\endlastfoot 
ATP13A2 & Bradykinesia [HP:0002067] & OMIM:606693 & 30/32 (94\%) & OMIM:617225 & 4/10 (40\%) & $9.2 \times 10^{-04}$ & 0.012\\
ATP13A2 & Bradykinesia [HP:0002067] & OMIM:606693 & 29/31 (94\%) & OMIM:617225 & 4/10 (40\%) & $1.0 \times 10^{-03}$ & 0.013\\
ATP13A2 & Parkinsonism [HP:0001300] & OMIM:606693 & 27/27 (100\%) & OMIM:617225 & 3/11 (27\%) & $3.4 \times 10^{-06}$ & $8.4 \times 10^{-05}$\\
ATP13A2 & Parkinsonism [HP:0001300] & OMIM:606693 & 27/27 (100\%) & OMIM:617225 & 3/11 (27\%) & $3.4 \times 10^{-06}$ & $8.1 \times 10^{-05}$\\
ATP13A2 & Bradykinesia [HP:0002067] & OMIM:606693 & 29/31 (94\%) & OMIM:617225 & 4/10 (40\%) & $1.0 \times 10^{-03}$ & 0.013\\
ATP13A2 & Parkinsonism [HP:0001300] & OMIM:606693 & 28/28 (100\%) & OMIM:617225 & 3/11 (27\%) & $2.7 \times 10^{-06}$ & $7.2 \times 10^{-05}$\\
BRD4 & Intrauterine growth retardation [HP:0001511] & NIPBL & 37/45 (82\%) & BRD4 & 2/9 (22\%) & $9.4 \times 10^{-04}$ & 0.031\\
EHMT1 & Attention deficit hyperactivity disorder [HP:0007018] & N Term Frameshift & 4/8 (50\%) & $\complement$ & 3/95 (3\%) & $5.0 \times 10^{-04}$ & 0.010\\
EHMT1 & Intellectual disability [HP:0001249] & N Term Frameshift & 4/8 (50\%) & $\complement$ & 107/116 (92\%) & 0.004 & 0.042\\
FBN1 & Hyperextensibility of the finger joints [HP:0001187] & fs last two & 2/2 (100\%) & $\complement$ & 1/90 (1\%) & $7.2 \times 10^{-04}$ & 0.009\\
FBN1 & Aortic root aneurysm [HP:0002616] & missense & 25/115 (22\%) & $\complement$ & 11/23 (48\%) & 0.017 & 0.047\\
FBN1 & Short stature [HP:0004322] & TB domain & 23/39 (59\%) & cbEGF & 0/24 (0\%) & $4.4 \times 10^{-07}$ & $3.5 \times 10^{-06}$\\
FBN1 & Short stature [HP:0004322] & missense & 32/78 (41\%) & $\complement$ & 1/13 (8\%) & 0.027 & 0.050\\
FBN1 & High palate [HP:0000218] & missense & 19/71 (27\%) & $\complement$ & 10/18 (56\%) & 0.026 & 0.050\\
FBN1 & Proportionate short stature [HP:0003508] & TB domain & 20/36 (56\%) & cbEGF & 0/24 (0\%) & $2.3 \times 10^{-06}$ & $9.4 \times 10^{-06}$\\
FBN1 & Ectopia lentis [HP:0001083] & TB domain & 9/18 (50\%) & cbEGF & 48/59 (81\%) & 0.013 & 0.021\\
FBN1 & Arachnodactyly [HP:0001166] & exon 37 & 0/8 (0\%) & $\complement$ & 52/95 (55\%) & 0.003 & 0.008\\
FBN1 & Tall stature [HP:0000098] & TB domain & 7/38 (18\%) & cbEGF & 21/40 (52\%) & 0.002 & 0.004\\
FBN1 & Ectopia lentis [HP:0001083] & exon 37 & 1/9 (11\%) & $\complement$ & 78/100 (78\%) & $1.1 \times 10^{-04}$ & $5.0 \times 10^{-04}$\\
FBN1 & Stiff skin [HP:0030053] & exon 37 & 8/9 (89\%) & $\complement$ & 0/50 (0\%) & $4.1 \times 10^{-09}$ & $3.7 \times 10^{-08}$\\
FBN1 & Ectopia lentis [HP:0001083] & missense & 68/87 (78\%) & $\complement$ & 11/22 (50\%) & 0.015 & 0.047\\
FBN1 & Thoracic aortic aneurysm [HP:0012727] & missense & 25/64 (39\%) & $\complement$ & 12/14 (86\%) & 0.002 & 0.013\\
FBN1 & Arachnodactyly [HP:0001166] & missense & 34/81 (42\%) & $\complement$ & 18/22 (82\%) & $1.0 \times 10^{-03}$ & 0.013\\
FBN1 & Severe short stature [HP:0003510] & TB domain & 15/36 (42\%) & cbEGF & 0/24 (0\%) & $1.4 \times 10^{-04}$ & $3.6 \times 10^{-04}$\\
FBXL4 & Feeding difficulties [HP:0011968] & missense: $1/\complement$ OR $\complement/\complement$ & 23/24 (96\%) & missense: $1/1$ & 13/27 (48\%) & $1.7 \times 10^{-04}$ & 0.004\\
FGD1 & Broad foot [HP:0001769] & Missense & 1/7 (14\%) & $\complement$ & 14/15 (93\%) & $6.2 \times 10^{-04}$ & 0.029\\
GLI3 & Y-shaped metatarsals [HP:0010567] & Fs in mid region or splice & 11/19 (58\%) & $\complement$ & 4/50 (8\%) & $3.2 \times 10^{-05}$ & $6.2 \times 10^{-04}$\\
GLI3 & Postaxial hand polydactyly [HP:0001162] & Variants in C-terminal third & 15/16 (94\%) & $\complement$ & 21/49 (43\%) & $3.4 \times 10^{-04}$ & 0.002\\
GLI3 & Preaxial foot polydactyly [HP:0001841] & Fs in mid region or splice & 5/25 (20\%) & $\complement$ & 32/57 (56\%) & 0.003 & 0.022\\
GLI3 & Postaxial foot polydactyly [HP:0001830] & Truncating variants in Exon 15 & 9/20 (45\%) & $\complement$ & 2/35 (6\%) & $8.9 \times 10^{-04}$ & 0.008\\
GLI3 & Postaxial foot polydactyly [HP:0001830] & Variants in C-terminal third & 9/16 (56\%) & $\complement$ & 2/39 (5\%) & $7.3 \times 10^{-05}$ & $1.0 \times 10^{-03}$\\
GLI3 & Y-shaped metacarpals [HP:0006042] & Fs in mid region or splice & 11/23 (48\%) & $\complement$ & 4/56 (7\%) & $9.9 \times 10^{-05}$ & $9.4 \times 10^{-04}$\\
GLI3 & Syndactyly [HP:0001159] & Variants in C-terminal third & 5/16 (31\%) & $\complement$ & 33/39 (85\%) & $2.2 \times 10^{-04}$ & 0.002\\
GLI3 & Syndactyly [HP:0001159] & Truncating variants in Exon 15 & 5/17 (29\%) & $\complement$ & 33/38 (87\%) & $4.8 \times 10^{-05}$ & $9.2 \times 10^{-04}$\\
GLI3 & Macrocephaly [HP:0000256] & Truncating variants in Exon 15 & 13/16 (81\%) & $\complement$ & 15/42 (36\%) & 0.003 & 0.018\\
GLI3 & Macrocephaly [HP:0000256] & Variants in C-terminal third & 13/15 (87\%) & $\complement$ & 15/43 (35\%) & $7.3 \times 10^{-04}$ & 0.003\\
GLI3 & Preaxial foot polydactyly [HP:0001841] & Truncating variants in Exon 15 & 7/28 (25\%) & $\complement$ & 30/54 (56\%) & 0.010 & 0.049\\
IKZF1 & Recurrent pneumonia [HP:0006532] & p.Asn159Ser & 7/9 (78\%) & $\complement$ variant & 7/39 (18\%) & $1.0 \times 10^{-03}$ & 0.030\\
ITPR1 & Nystagmus [HP:0000639] & SV Deletion & 17/17 (100\%) & $\complement$ & 61/87 (70\%) & 0.006 & 0.015\\
ITPR1 & Delayed ability to walk [HP:0031936] & GS Hotspot & 14/14 (100\%) & $\complement$ & 40/67 (60\%) & 0.003 & 0.029\\
ITPR1 & Delayed ability to sit [HP:0025336] & IP3 binding & 11/11 (100\%) & $\complement$ & 42/70 (60\%) & 0.013 & 0.045\\
ITPR1 & Delayed ability to sit [HP:0025336] & GS Hotspot & 13/13 (100\%) & $\complement$ & 40/68 (59\%) & 0.003 & 0.029\\
ITPR1 & Delayed speech and language development [HP:0000750] & IP3 binding & 13/13 (100\%) & $\complement$ & 37/63 (59\%) & 0.003 & 0.017\\
ITPR1 & Aniridia [HP:0000526] & GS Hotspot & 14/20 (70\%) & $\complement$ & 6/48 (12\%) & $6.1 \times 10^{-06}$ & $1.5 \times 10^{-04}$\\
ITPR1 & Motor delay [HP:0001270] & IP3 binding & 24/24 (100\%) & $\complement$ & 63/89 (71\%) & 0.002 & 0.017\\
ITPR1 & Delayed speech and language development [HP:0000750] & SV Deletion & 0/19 (0\%) & $\complement$ & 50/57 (88\%) & $1.7 \times 10^{-12}$ & $7.2 \times 10^{-12}$\\
ITPR1 & Delayed ability to walk [HP:0031936] & SV Deletion & 0/19 (0\%) & $\complement$ & 54/62 (87\%) & $1.5 \times 10^{-12}$ & $7.2 \times 10^{-12}$\\
ITPR1 & Neurodevelopmental delay [HP:0012758] & IP3 binding & 29/29 (100\%) & $\complement$ & 70/90 (78\%) & 0.003 & 0.017\\
ITPR1 & Nystagmus [HP:0000639] & IP3 binding & 25/26 (96\%) & $\complement$ & 53/78 (68\%) & 0.003 & 0.017\\
ITPR1 & Delayed ability to walk [HP:0031936] & IP3 binding & 13/13 (100\%) & $\complement$ & 41/68 (60\%) & 0.004 & 0.017\\
ITPR1 & Global developmental delay [HP:0001263] & SV Deletion & 0/19 (0\%) & $\complement$ & 48/57 (84\%) & $1.8 \times 10^{-11}$ & $5.4 \times 10^{-11}$\\
ITPR1 & Motor delay [HP:0001270] & GS Hotspot & 19/19 (100\%) & $\complement$ & 68/94 (72\%) & 0.006 & 0.030\\
ITPR1 & Delayed gross motor development [HP:0002194] & GS Hotspot & 18/18 (100\%) & $\complement$ & 57/83 (69\%) & 0.005 & 0.030\\
ITPR1 & Neurodevelopmental delay [HP:0012758] & SV Deletion & 0/19 (0\%) & $\complement$ & 99/100 (99\%) & $4.1 \times 10^{-21}$ & $8.5 \times 10^{-20}$\\
ITPR1 & Motor delay [HP:0001270] & SV Deletion & 0/19 (0\%) & $\complement$ & 87/94 (93\%) & $3.9 \times 10^{-16}$ & $4.1 \times 10^{-15}$\\
ITPR1 & Delayed gross motor development [HP:0002194] & SV Deletion & 0/19 (0\%) & $\complement$ & 75/82 (91\%) & $4.0 \times 10^{-15}$ & $2.8 \times 10^{-14}$\\
ITPR1 & Delayed gross motor development [HP:0002194] & IP3 binding & 18/18 (100\%) & $\complement$ & 57/83 (69\%) & 0.005 & 0.022\\
ITPR1 & Delayed ability to sit [HP:0025336] & SV Deletion & 0/19 (0\%) & $\complement$ & 53/62 (85\%) & $4.6 \times 10^{-12}$ & $1.6 \times 10^{-11}$\\
KCNH5 & Epileptic encephalopathy [HP:0200134] & Arg327His & 15/15 (100\%) & Arg333His & 0/3 (0\%) & $1.0 \times 10^{-03}$ & 0.016\\
KDM6A & Intellectual disability, severe [HP:0010864] & FEMALE & 7/25 (28\%) & MALE & 14/18 (78\%) & 0.002 & 0.008\\
KDM6A & Pulmonic stenosis [HP:0001642] & p.Asn891ValfsTer27 & 2/2 (100\%) & $\complement$ & 0/59 (0\%) & $5.5 \times 10^{-04}$ & 0.013\\
Kabuki & Feeding difficulties [HP:0011968] & OMIM:147920 & 8/25 (32\%) & OMIM:300867 & 55/63 (87\%) & $7.4 \times 10^{-07}$ & $2.1 \times 10^{-05}$\\
Kabuki & Motor delay [HP:0001270] & OMIM:147920 & 4/10 (40\%) & OMIM:300867 & 58/61 (95\%) & $1.0 \times 10^{-04}$ & $1.0 \times 10^{-03}$\\
LDS 1 and 2 & Bilateral tonic-clonic seizure with focal onset [HP:0007334] & MAPT: $1/1$ or $1/\complement$  & 0/18 (0\%) & $\complement/\complement$  & 7/9 (78\%) & $4.1 \times 10^{-05}$ & $1.0 \times 10^{-03}$\\
LDS 1 and 3 & Hypertelorism [HP:0000316] & OMIM:609192 & 15/19 (79\%) & OMIM:613795 & 13/35 (37\%) & 0.004 & 0.024\\
LDS 1 and 3 & Osteoarthritis [HP:0002758] & OMIM:609192 & 0/11 (0\%) & OMIM:613795 & 26/38 (68\%) & $4.6 \times 10^{-05}$ & $9.7 \times 10^{-04}$\\
LDS 1 and 3 & Scoliosis [HP:0002650] & OMIM:609192 & 18/21 (86\%) & OMIM:613795 & 20/43 (47\%) & 0.003 & 0.024\\
LDS 1 and 3 & Aortic aneurysm [HP:0004942] & OMIM:609192 & 11/11 (100\%) & OMIM:613795 & 26/48 (54\%) & 0.004 & 0.024\\
LDS 3 and 6 & Thoracic aortic aneurysm [HP:0012727] & OMIM:613795 & 0/22 (0\%) & OMIM:619656 & 10/15 (67\%) & $8.6 \times 10^{-06}$ & $1.8 \times 10^{-04}$\\
LMNA & Atrioventricular block [HP:0001678] & Upstream Tail (1-383) & 17/35 (49\%) & $\complement$ & 8/117 (7\%) & $1.2 \times 10^{-07}$ & $9.5 \times 10^{-07}$\\
LMNA & Lower-limb joint contracture [HP:0005750] & Upstream of NLS & 22/82 (27\%) & $\complement$ & 19/27 (70\%) & $8.2 \times 10^{-05}$ & $3.6 \times 10^{-04}$\\
LMNA & Elbow contracture [HP:0034391] & NLS Upstream & 21/83 (25\%) & $\complement$ & 18/26 (69\%) & $1.0 \times 10^{-04}$ & $3.8 \times 10^{-04}$\\
LMNA & Limb joint contracture [HP:0003121] & NLS Upstream & 23/83 (28\%) & $\complement$ & 19/27 (70\%) & $1.7 \times 10^{-04}$ & $4.7 \times 10^{-04}$\\
LMNA & Foot joint contracture [HP:0008366] & NLS Upstream & 21/81 (26\%) & $\complement$ & 19/27 (70\%) & $6.2 \times 10^{-05}$ & $3.4 \times 10^{-04}$\\
LMNA & Lower-limb joint contracture [HP:0005750] & NLS Upstream & 22/82 (27\%) & $\complement$ & 19/27 (70\%) & $8.2 \times 10^{-05}$ & $3.6 \times 10^{-04}$\\
LMNA & Muscle weakness [HP:0001324] & Gly608= & 0/15 (0\%) & $\complement$ & 63/124 (51\%) & $6.1 \times 10^{-05}$ & $1.5 \times 10^{-04}$\\
LMNA & Limb joint contracture [HP:0003121] & NLS Upstream & 19/79 (24\%) & $\complement$ & 23/31 (74\%) & $2.1 \times 10^{-06}$ & $6.2 \times 10^{-06}$\\
LMNA & Limb joint contracture [HP:0003121] & Upstream Tail (1-383) & 19/79 (24\%) & $\complement$ & 23/31 (74\%) & $2.1 \times 10^{-06}$ & $6.2 \times 10^{-06}$\\
LMNA & Achilles tendon contracture [HP:0001771] & Upstream Tail (1-383) & 17/81 (21\%) & $\complement$ & 23/34 (68\%) & $3.4 \times 10^{-06}$ & $9.0 \times 10^{-06}$\\
LMNA & Elbow contracture [HP:0034391] & Upstream Tail (1-383) & 17/79 (22\%) & $\complement$ & 22/30 (73\%) & $9.6 \times 10^{-07}$ & $4.6 \times 10^{-06}$\\
LMNA & Achilles tendon contracture [HP:0001771] & NLS Upstream & 21/85 (25\%) & $\complement$ & 19/30 (63\%) & $2.7 \times 10^{-04}$ & $6.5 \times 10^{-04}$\\
LMNA & Upper-limb joint contracture [HP:0100360] & NLS Upstream & 21/81 (26\%) & $\complement$ & 18/26 (69\%) & $1.2 \times 10^{-04}$ & $3.9 \times 10^{-04}$\\
LMNA & Loss of truncal subcutaneous adipose tissue [HP:0009002] & missense & 104/104 (100\%) & $\complement$ & 4/11 (36\%) & $7.5 \times 10^{-09}$ & $1.3 \times 10^{-07}$\\
LMNA & Achilles tendon contracture [HP:0001771] & Upstream of NLS & 21/85 (25\%) & $\complement$ & 19/30 (63\%) & $2.7 \times 10^{-04}$ & $6.5 \times 10^{-04}$\\
LMNA & Proximal muscle weakness [HP:0003701] & Gly608= & 0/15 (0\%) & $\complement$ & 53/114 (46\%) & $3.6 \times 10^{-04}$ & $4.5 \times 10^{-04}$\\
LMNA & Upper-limb joint contracture [HP:0100360] & NLS Upstream & 17/77 (22\%) & $\complement$ & 22/30 (73\%) & $1.4 \times 10^{-06}$ & $5.3 \times 10^{-06}$\\
LMNA & Atrioventricular block [HP:0001678] & NLS Upstream & 17/35 (49\%) & $\complement$ & 8/117 (7\%) & $1.2 \times 10^{-07}$ & $9.5 \times 10^{-07}$\\
LMNA & Lipodystrophy [HP:0009125] & Gly608= & 15/15 (100\%) & $\complement$ & 127/236 (54\%) & $1.9 \times 10^{-04}$ & $3.1 \times 10^{-04}$\\
LMNA & Dilated cardiomyopathy [HP:0001644] & NLS Upstream & 35/69 (51\%) & $\complement$ & 5/103 (5\%) & $2.2 \times 10^{-12}$ & $2.6 \times 10^{-11}$\\
LMNA & Upper-limb joint contracture [HP:0100360] & Upstream Tail (1-383) & 17/77 (22\%) & $\complement$ & 22/30 (73\%) & $1.4 \times 10^{-06}$ & $5.3 \times 10^{-06}$\\
LMNA & Lipodystrophy [HP:0009125] & Upstream of NLS & 10/93 (11\%) & $\complement$ & 132/158 (84\%) & $1.7 \times 10^{-31}$ & $3.8 \times 10^{-30}$\\
LMNA & Elbow contracture [HP:0034391] & NLS Upstream & 17/79 (22\%) & $\complement$ & 22/30 (73\%) & $9.6 \times 10^{-07}$ & $4.6 \times 10^{-06}$\\
LMNA & Foot joint contracture [HP:0008366] & NLS Upstream & 17/77 (22\%) & $\complement$ & 23/31 (74\%) & $6.7 \times 10^{-07}$ & $4.0 \times 10^{-06}$\\
LMNA & Atrioventricular block [HP:0001678] & Upstream of NLS & 17/36 (47\%) & $\complement$ & 8/116 (7\%) & $2.1 \times 10^{-07}$ & $1.5 \times 10^{-06}$\\
LMNA & Upper-limb joint contracture [HP:0100360] & Upstream of NLS & 21/81 (26\%) & $\complement$ & 18/26 (69\%) & $1.2 \times 10^{-04}$ & $3.9 \times 10^{-04}$\\
LMNA & Pancreatitis [HP:0001733] & Upstream of NLS & 4/7 (57\%) & $\complement$ & 14/110 (13\%) & 0.011 & 0.023\\
LMNA & Dilated cardiomyopathy [HP:0001644] & Upstream Tail (1-383) & 35/69 (51\%) & $\complement$ & 5/103 (5\%) & $2.2 \times 10^{-12}$ & $2.6 \times 10^{-11}$\\
LMNA & Elevated hemoglobin A1c [HP:0040217] & A & 0/15 (0\%) & B & 79/110 (72\%) & $5.7 \times 10^{-08}$ & $2.8 \times 10^{-07}$\\
LMNA & Elevated hemoglobin A1c [HP:0040217] & missense & 73/101 (72\%) & $\complement$ & 6/24 (25\%) & $3.1 \times 10^{-05}$ & $2.6 \times 10^{-04}$\\
LMNA & Muscle weakness [HP:0001324] & A & 0/15 (0\%) & B & 63/124 (51\%) & $6.1 \times 10^{-05}$ & $1.5 \times 10^{-04}$\\
LMNA & Atrioventricular block [HP:0001678] & NLS Upstream & 17/36 (47\%) & $\complement$ & 8/116 (7\%) & $2.1 \times 10^{-07}$ & $1.5 \times 10^{-06}$\\
LMNA & Dilated cardiomyopathy [HP:0001644] & Upstream of NLS & 35/70 (50\%) & $\complement$ & 5/102 (5\%) & $4.2 \times 10^{-12}$ & $4.6 \times 10^{-11}$\\
LMNA & Lipodystrophy [HP:0009125] & NLS Upstream & 9/88 (10\%) & $\complement$ & 133/163 (82\%) & $1.7 \times 10^{-29}$ & $4.1 \times 10^{-28}$\\
LMNA & Elevated hemoglobin A1c [HP:0040217] & Gly608= & 0/15 (0\%) & $\complement$ & 79/110 (72\%) & $5.7 \times 10^{-08}$ & $2.8 \times 10^{-07}$\\
LMNA & Elbow contracture [HP:0034391] & Upstream of NLS & 21/83 (25\%) & $\complement$ & 18/26 (69\%) & $1.0 \times 10^{-04}$ & $3.8 \times 10^{-04}$\\
LMNA & Achilles tendon contracture [HP:0001771] & NLS Upstream & 17/81 (21\%) & $\complement$ & 23/34 (68\%) & $3.4 \times 10^{-06}$ & $9.0 \times 10^{-06}$\\
LMNA & Lipodystrophy [HP:0009125] & NLS Upstream & 10/93 (11\%) & $\complement$ & 132/158 (84\%) & $1.7 \times 10^{-31}$ & $3.8 \times 10^{-30}$\\
LMNA & Lipodystrophy [HP:0009125] & Upstream Tail (1-383) & 9/88 (10\%) & $\complement$ & 133/163 (82\%) & $1.7 \times 10^{-29}$ & $4.1 \times 10^{-28}$\\
LMNA & Foot joint contracture [HP:0008366] & Upstream of NLS & 21/81 (26\%) & $\complement$ & 19/27 (70\%) & $6.2 \times 10^{-05}$ & $3.4 \times 10^{-04}$\\
LMNA & Lipodystrophy [HP:0009125] & A & 15/15 (100\%) & B & 127/236 (54\%) & $1.9 \times 10^{-04}$ & $3.1 \times 10^{-04}$\\
LMNA & Foot joint contracture [HP:0008366] & Upstream Tail (1-383) & 17/77 (22\%) & $\complement$ & 23/31 (74\%) & $6.7 \times 10^{-07}$ & $4.0 \times 10^{-06}$\\
LMNA & Lower-limb joint contracture [HP:0005750] & Upstream Tail (1-383) & 18/78 (23\%) & $\complement$ & 23/31 (74\%) & $1.5 \times 10^{-06}$ & $5.3 \times 10^{-06}$\\
LMNA & Proximal muscle weakness [HP:0003701] & A & 0/15 (0\%) & B & 53/114 (46\%) & $3.6 \times 10^{-04}$ & $4.5 \times 10^{-04}$\\
LMNA & Lower-limb joint contracture [HP:0005750] & NLS Upstream & 18/78 (23\%) & $\complement$ & 23/31 (74\%) & $1.5 \times 10^{-06}$ & $5.3 \times 10^{-06}$\\
LMNA & Pancreatitis [HP:0001733] & NLS Upstream & 4/7 (57\%) & $\complement$ & 14/110 (13\%) & 0.011 & 0.023\\
LMNA & Limb joint contracture [HP:0003121] & Upstream of NLS & 23/83 (28\%) & $\complement$ & 19/27 (70\%) & $1.7 \times 10^{-04}$ & $4.7 \times 10^{-04}$\\
LMNA & Dilated cardiomyopathy [HP:0001644] & NLS Upstream & 35/70 (50\%) & $\complement$ & 5/102 (5\%) & $4.2 \times 10^{-12}$ & $4.6 \times 10^{-11}$\\
MPV17 & Peripheral axonal neuropathy [HP:0003477] & Pro98Leu: $1/1$ & 3/3 (100\%) & Pro98Leu: $1/\complement$ OR  $\complement/\complement$ & 1/22 (5\%) & 0.002 & 0.033\\
NBAS & Decreased circulating IgG concentration [HP:0004315] & missense: $1/1$ & 1/12 (8\%) & missense: $1/\complement$ or $\complement/\complement$ & 15/23 (65\%) & 0.002 & 0.019\\
NF1 & Optic nerve glioma [HP:0009734] & Leu847Pro & 15/33 (45\%) & $\complement$ & 24/143 (17\%) & $8.6 \times 10^{-04}$ & 0.002\\
NF1 & Lisch nodules [HP:0009737] & Leu847Pro & 22/42 (52\%) & $\complement$ & 61/242 (25\%) & $7.5 \times 10^{-04}$ & 0.002\\
NF1 & Neurofibroma [HP:0001067] & p.Arg1830 & 5/8 (62\%) & $\complement$ & 153/162 (94\%) & 0.012 & 0.031\\
NF1 & Axillary freckling [HP:0000997] & p.Arg1830 & 20/79 (25\%) & $\complement$ & 105/175 (60\%) & $3.7 \times 10^{-07}$ & $1.2 \times 10^{-06}$\\
NF1 & Axillary freckling [HP:0000997] & Leu847Pro & 50/61 (82\%) & $\complement$ & 75/193 (39\%) & $3.5 \times 10^{-09}$ & $4.3 \times 10^{-08}$\\
NF1 & Inguinal freckling [HP:0030052] & Leu847Pro & 34/60 (57\%) & $\complement$ & 58/189 (31\%) & $3.9 \times 10^{-04}$ & 0.002\\
NF1 & Inguinal freckling [HP:0030052] & p.Arg1830 & 8/79 (10\%) & $\complement$ & 84/170 (49\%) & $4.9 \times 10^{-10}$ & $2.4 \times 10^{-09}$\\
NF1 & Freckling [HP:0001480] & Leu847Pro & 54/54 (100\%) & $\complement$ & 223/301 (74\%) & $5.3 \times 10^{-07}$ & $3.2 \times 10^{-06}$\\
NF1 & Freckling [HP:0001480] & p.Arg1830 & 76/133 (57\%) & $\complement$ & 201/222 (91\%) & $6.3 \times 10^{-13}$ & $6.3 \times 10^{-12}$\\
NF1 & Axillary freckling [HP:0000997] & Met992del & 0/14 (0\%) & $\complement$ & 125/240 (52\%) & $8.6 \times 10^{-05}$ & $4.3 \times 10^{-04}$\\
PTPN11 & Hypertelorism [HP:0000316] & Missense & 37/41 (90\%) & $\complement$ & 0/12 (0\%) & $6.8 \times 10^{-09}$ & $2.1 \times 10^{-08}$\\
PTPN11 & Webbed neck [HP:0000465] & Missense & 15/20 (75\%) & $\complement$ & 0/12 (0\%) & $2.9 \times 10^{-05}$ & $4.4 \times 10^{-05}$\\
PTPN11 & Pulmonic stenosis [HP:0001642] & Missense & 18/34 (53\%) & $\complement$ & 0/12 (0\%) & $1.0 \times 10^{-03}$ & $1.0 \times 10^{-03}$\\
RNU4-2 & Severe global developmental delay [HP:0011344] & insertion & 35/41 (85\%) & $\complement$ & 0/4 (0\%) & $1.0 \times 10^{-03}$ & 0.037\\
RNU4-2 & Moderate global developmental delay [HP:0011343] & insertion & 6/41 (15\%) & $\complement$ & 4/4 (100\%) & $1.0 \times 10^{-03}$ & 0.037\\
RPGRIP1 & Nystagmus [HP:0000639] & OMIM:613826 & 64/66 (97\%) & OMIM:608194 & 11/16 (69\%) & 0.003 & 0.020\\
RPGRIP1 & Eye poking [HP:0001483] & 1107del: $1/1$ OR $1/\complement$ & 16/16 (100\%) &  1107del: $\complement/\complement$ & 19/41 (46\%) & $1.3 \times 10^{-04}$ & 0.002\\
RPGRIP1 & Very low visual acuity [HP:0032122] & OMIM:613826 & 35/39 (90\%) & OMIM:608194 & 4/16 (25\%) & $5.2 \times 10^{-06}$ & $7.8 \times 10^{-05}$\\
Robinow & Cleft palate [HP:0000175] & OMIM:268310 & 0/17 (0\%) & OMIM:616331 & 5/8 (62\%) & $1.0 \times 10^{-03}$ & 0.028\\
Robinow & Hearing impairment [HP:0000365] & OMIM:268310 & 3/22 (14\%) & OMIM:616331 & 7/7 (100\%) & $7.7 \times 10^{-05}$ & 0.003\\
Robinow & Short stature [HP:0004322] & OMIM:268310 & 29/29 (100\%) & OMIM:616331 & 3/11 (27\%) & $2.2 \times 10^{-06}$ & $1.7 \times 10^{-04}$\\
Robinow & Mesomelia [HP:0003027] & OMIM:268310 & 31/31 (100\%) & OMIM:616331 & 10/15 (67\%) & 0.002 & 0.043\\
Robinow & Orofacial cleft [HP:0000202] & OMIM:268310 & 5/22 (23\%) & OMIM:616331 & 5/5 (100\%) & 0.003 & 0.049\\
SAMD9L & Pancytopenia [HP:0001876] & Arg986Cys & 4/6 (67\%) & Ser626Leu & 0/9 (0\%) & 0.011 & 0.022\\
SAMD9L & Thrombocytopenia [HP:0001873] & Arg986Cys & 7/9 (78\%) & Ser626Leu & 0/9 (0\%) & 0.002 & 0.007\\
SAMD9L & Neutropenia [HP:0001875] & Arg986Cys & 7/9 (78\%) & Ser626Leu & 0/9 (0\%) & 0.002 & 0.007\\
SATB2 & Cleft palate [HP:0000175] & Missense & 11/49 (22\%) & $\complement$ & 59/105 (56\%) & $1.1 \times 10^{-04}$ & 0.002\\
SCN2A & Neurodevelopmental abnormality [HP:0012759] & I repeat & 48/65 (74\%) & $\complement$ & 198/218 (91\%) & $1.0 \times 10^{-03}$ & 0.009\\
SCN2A & Intellectual disability [HP:0001249] & Missense & 144/198 (73\%) & $\complement$ & 34/34 (100\%) & $9.4 \times 10^{-05}$ & $2.3 \times 10^{-04}$\\
SCN2A & Focal-onset seizure [HP:0007359] & Missense & 141/170 (83\%) & $\complement$ & 8/33 (24\%) & $8.7 \times 10^{-11}$ & $6.5 \times 10^{-10}$\\
SCN2A & Generalized-onset seizure [HP:0002197] & Missense & 104/133 (78\%) & $\complement$ & 6/31 (19\%) & $1.4 \times 10^{-09}$ & $5.4 \times 10^{-09}$\\
SCN2A & Motor seizure [HP:0020219] & Missense & 146/175 (83\%) & $\complement$ & 6/31 (19\%) & $4.5 \times 10^{-12}$ & $6.8 \times 10^{-11}$\\
SCN2A & Autism [HP:0000717] & Missense & 59/146 (40\%) & $\complement$ & 33/43 (77\%) & $2.7 \times 10^{-05}$ & $8.1 \times 10^{-05}$\\
SCN2A & Seizure [HP:0001250] & Missense & 298/327 (91\%) & $\complement$ & 28/53 (53\%) & $1.6 \times 10^{-10}$ & $7.9 \times 10^{-10}$\\
SCN2A & Neurodevelopmental abnormality [HP:0012759] & Missense & 201/238 (84\%) & $\complement$ & 45/45 (100\%) & $1.0 \times 10^{-03}$ & 0.003\\
SCN2A & Intellectual disability [HP:0001249] & I repeat & 21/42 (50\%) & $\complement$ & 157/190 (83\%) & $2.6 \times 10^{-05}$ & $3.9 \times 10^{-04}$\\
SCO2 & Hypertrophic cardiomyopathy [HP:0001639] & Glu140Lys: $1/1$ & 2/6 (33\%) & Glu140Lys: $1/\complement$ OR $\complement/\complement$ & 13/13 (100\%) & 0.004 & 0.027\\
SEC61A1 & Recurrent lower respiratory tract infections [HP:0002783] & p.Val85Asp & 6/6 (100\%) & $\complement$ variant & 0/5 (0\%) & 0.002 & 0.039\\
SETD2 & Macrocephaly [HP:0000256] & Arg1740Trp & 0/11 (0\%) & $\complement$ & 19/28 (68\%) & $1.5 \times 10^{-04}$ & $1.0 \times 10^{-03}$\\
SETD2 & Macrocephaly [HP:0000256] & Missense & 4/24 (17\%) & $\complement$ & 15/15 (100\%) & $1.5 \times 10^{-07}$ & $4.2 \times 10^{-06}$\\
SETD2 & Ventriculomegaly [HP:0002119] & Arg1740Trp & 4/4 (100\%) & $\complement$ & 2/17 (12\%) & 0.003 & 0.009\\
SETD2 & Scoliosis [HP:0002650] & Arg1740Trp & 6/6 (100\%) & $\complement$ & 2/14 (14\%) & $7.2 \times 10^{-04}$ & 0.003\\
SETD2 & Delayed ability to walk [HP:0031936] & Arg1740Trp & 8/8 (100\%) & $\complement$ & 1/10 (10\%) & $4.1 \times 10^{-04}$ & 0.002\\
SETD2 & Hypertelorism [HP:0000316] & Arg1740Trp & 11/11 (100\%) & $\complement$ & 5/23 (22\%) & $1.5 \times 10^{-05}$ & $1.8 \times 10^{-04}$\\
SETD2 & Severe global developmental delay [HP:0011344] & Arg1740Trp & 9/9 (100\%) & $\complement$ & 0/12 (0\%) & $3.4 \times 10^{-06}$ & $8.2 \times 10^{-05}$\\
SETD2 & Wide nasal bridge [HP:0000431] & Arg1740Trp & 9/9 (100\%) & $\complement$ & 2/9 (22\%) & 0.002 & 0.009\\
SMAD3 & Osteoarthritis [HP:0002758] & p.Arg287Trp & 19/19 (100\%) & $\complement$ & 7/19 (37\%) & $3.7 \times 10^{-05}$ & $8.6 \times 10^{-04}$\\
SMARCB1 & Neuroepithelial neoplasm [HP:0030063] & Structural variant & 2/2 (100\%) & $\complement$ & 0/17 (0\%) & 0.006 & 0.012\\
SMARCB1 & Atypical teratoid/rhabdoid tumor [HP:0034401] & Structural variant & 8/9 (89\%) & $\complement$ & 2/19 (11\%) & $1.2 \times 10^{-04}$ & $4.0 \times 10^{-04}$\\
SMARCB1 & Neoplasm by anatomical site [HP:0011793] & Structural variant & 3/3 (100\%) & $\complement$ & 3/20 (15\%) & 0.011 & 0.019\\
SMARCB1 & Embryonal neoplasm [HP:0002898] & Structural variant & 8/8 (100\%) & $\complement$ & 2/19 (11\%) & $2.0 \times 10^{-05}$ & $1.0 \times 10^{-04}$\\
SMARCB1 & Neoplasm of the nervous system [HP:0004375] & Structural variant & 2/2 (100\%) & $\complement$ & 2/19 (11\%) & 0.029 & 0.041\\
SMARCB1 & Rhabdoid tumor [HP:0034557] & Structural variant & 4/4 (100\%) & $\complement$ & 2/19 (11\%) & 0.002 & 0.004\\
SMARCB1 & Neoplasm by histology [HP:0011792] & Structural variant & 11/11 (100\%) & $\complement$ & 4/21 (19\%) & $1.1 \times 10^{-05}$ & $1.0 \times 10^{-04}$\\
SMARCC2 & Autistic behavior [HP:0000729] & c.3222del & 7/8 (88\%) & $\complement$ & 13/51 (25\%) & $1.0 \times 10^{-03}$ & 0.017\\
SMARCC2 & Intellectual disability [HP:0001249] & c.3222del & 1/6 (17\%) & $\complement$ & 49/52 (94\%) & $7.0 \times 10^{-05}$ & 0.002\\
SMARCC2 & Mild global developmental delay [HP:0011342] & N term & 11/15 (73\%) & $\complement$ & 10/43 (23\%) & $1.0 \times 10^{-03}$ & 0.027\\
SUOX & Microcephaly [HP:0000252] & hdim: $1/1$ OR $1/\complement$ & 0/9 (0\%) & hdim:  $\complement/\complement$ & 10/12 (83\%) & $2.2 \times 10^{-04}$ & 0.003\\
TBCK & Macroglossia [HP:0000158] & R126*: $1/1$ & 11/12 (92\%) & R126*:  $1/\complement$ OR  $\complement/\complement$ & 3/22 (14\%) & $1.3 \times 10^{-05}$ & $3.4 \times 10^{-04}$\\
TBCK & Developmental regression [HP:0002376] & R126*: 1/1 & 9/12 (75\%) & R126*:  $1/\complement$ OR  $\complement/\complement$ & 2/22 (9\%) & $1.8 \times 10^{-04}$ & 0.002\\
TBX1 & Narrow nose [HP:0000460] & Tyr418PhefsTer42 & 5/5 (100\%) & $\complement$ & 0/6 (0\%) & 0.002 & 0.015\\
TBX1 & Global developmental delay [HP:0001263] & Tyr418PhefsTer42 & 5/5 (100\%) & $\complement$ & 3/20 (15\%) & $1.0 \times 10^{-03}$ & 0.015\\
TBX5 & Ventricular septal defect [HP:0001629] & missense & 31/60 (52\%) & $\complement$ & 30/30 (100\%) & $4.6 \times 10^{-07}$ & $8.8 \times 10^{-06}$\\
TBX5 & Ventricular septal defect [HP:0001629] & Arg237Gln & 0/17 (0\%) & $\complement$ & 61/73 (84\%) & $5.6 \times 10^{-11}$ & $1.1 \times 10^{-09}$\\
TGFBR1 & Hypertelorism [HP:0000316] & MSSE var & 0/18 (0\%) & $\complement$ & 15/19 (79\%) & $5.0 \times 10^{-07}$ & $3.0 \times 10^{-06}$\\
TGFBR1 & Arterial tortuosity [HP:0005116] & MSSE var & 1/19 (5\%) & $\complement$ & 8/16 (50\%) & 0.005 & 0.020\\
TGFBR1 & Self-healing squamous epithelioma [HP:0034720] & MSSE var & 18/19 (95\%) & $\complement$ & 0/21 (0\%) & $1.7 \times 10^{-10}$ & $2.0 \times 10^{-09}$\\
TGFBR1 & Self-healing squamous epithelioma [HP:0034720] & Gly52Arg & 7/7 (100\%) & $\complement$ & 11/33 (33\%) & 0.002 & 0.005\\
TGFBR1 & Hypertelorism [HP:0000316] & Gly52Arg & 0/7 (0\%) & $\complement$ & 15/30 (50\%) & 0.028 & 0.042\\
U2AF2 & Deeply set eye [HP:0000490] & r149W & 10/10 (100\%) & $\complement$ & 10/29 (34\%) & $4.4 \times 10^{-04}$ & 0.020\\
U2AF2 & Deeply set eye [HP:0000490] & R149,R150 variants & 10/10 (100\%) & $\complement$ & 10/29 (34\%) & $4.4 \times 10^{-04}$ & 0.020\\
UMOD & Hyperuricemia [HP:0002149] & cysteine & 38/41 (93\%) & $\complement$ & 26/48 (54\%) & $4.5 \times 10^{-05}$ & $2.7 \times 10^{-04}$\\
UMOD & Hyperuricemia [HP:0002149] & EGF & 14/32 (44\%) & $\complement$ & 50/57 (88\%) & $1.8 \times 10^{-05}$ & $1.1 \times 10^{-04}$\\
WWOX & Bilateral tonic-clonic seizure with focal onset [HP:0007334] & MAPT $1/1$ OR  $1/\complement$ & 0/18 (0\%) &  $\complement/\complement$ & 7/9 (78\%) & $4.1 \times 10^{-05}$ & $1.0 \times 10^{-03}$\\
ZFX & Hyperparathyroidism [HP:0000843] & missense & 7/9 (78\%) & $\complement$ & 0/5 (0\%) & 0.021 & 0.021\\
ZMYM3 & Hypospadias [HP:0000047] & R441 & 6/10 (60\%) & $\complement$ & 2/22 (9\%) & 0.005 & 0.022\\
ZMYM3 & Abnormal aortic valve cusp morphology [HP:0031567] & R441 & 4/8 (50\%) & $\complement$ & 0/22 (0\%) & 0.003 & 0.019\\
ZMYM3 & Cupped ear [HP:0000378] & R441 & 7/10 (70\%) & $\complement$ & 1/23 (4\%) & $2.0 \times 10^{-04}$ & 0.003\\
ZMYM3 & Bicuspid aortic valve [HP:0001647] & R441 & 4/10 (40\%) & $\complement$ & 0/22 (0\%) & 0.006 & 0.022\\
\hline
\end{longtable}
\end{scriptsize}
\end{center}